Jacob Jorns, MD
Urology · Gulfport, MSNPI 1871737064
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,215, 2.6 times the $471 reported in 2019.
Across 169 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$732
- AbbVie$664
- Astellas Pharma US Inc$625
- Johnson & Johnson$311
- Urogen Pharma, Inc.$222
- Procept Biorobotics Corporation$201
- plus $2K from 26 others
Across 1 payment — averaging $7000.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Cornerstone Urology Network, LLC$7K
What the payments were for
- Food & beverage$4,18898%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 9 | $732 |
| AbbVie(2 entities) | 48 | $664 |
| Astellas Pharma US Inc | 30 | $625 |
| Johnson & Johnson | 7 | $311 |
| Urogen Pharma, Inc. | 8 | $222 |
| Procept Biorobotics Corporation | 5 | $201 |
| Urovant Sciences Inc | 4 | $174 |
| Olympus America Inc. | 3 | $161 |
| Sumitomo Pharma America, Inc. | 8 | $131 |
| Endo USA, Inc. | 6 | $127 |
| Pfizer | 7 | $118 |
| Siemens Medical Solutions USA, Inc. | 1 | $92 |
| Endo Pharmaceuticals Inc. | 4 | $83 |
| Coloplast | 3 | $78 |
| Medtronic | 3 | $73 |
| Ferring Pharmaceuticals Inc. | 3 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $59 |
| Antares Pharma, Inc. | 3 | $53 |
| Tolmar Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 2 | $37 |
| Immunitybio, Inc. | 1 | $34 |
| Blue Earth Diagnostics | 1 | $27 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Myovant Sciences Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $20 |
| Photocure Inc | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $17 |
| Ambu Inc. | 1 | $14 |
| Profound Medical Corp. | 1 | $13 |
| Bayer | 1 | $13 |
| ABC Home Medical Supply, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tria Firm$270
- RYBREVANT$148
- CARVYKTI$148
- GENERAL KIDNEY STONE DISEASE$125
- SpaceOAR VUE System - 10mL$121
- LithoVue$120
- MYRBETRIQ$116
- GEMTESA$114
How this compares
$4,277 in reported general payments places this provider in the 60th percentile of 94 urology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 96 | $48,612 |
| GemtesaVibegron | 70 | $44,964 |
| OrgovyxRelugolix | 11 | $28,718 |
| NitrofurantoinNitrofurantoin Macrocrystal | 148 | $6,908 |
| Tamsulosin Hcl | 518 | $5,666 |
| Solifenacin Succinate | 41 | $2,539 |
| Trimethoprim | 29 | $1,283 |
| Doxycycline Hyclate | 58 | $1,061 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,005 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 56 | $868 |
| Finasteride | 66 | $838 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 66 | $780 |
| Silodosin | 13 | $508 |
| Testosterone Cypionate | 15 | $484 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $252 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $131 | $73,68281 claims |
| Astellas Pharma US IncMyrbetriq | $625 | $48,61296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 94 urology providers in Mississippi.
Other urology in Gulfport
- William HughesGulfport$8K
- Paige WhiteGulfport$7K
- Joseph CottoneGulfport$6K
- Sean DouglasHattiesburg$40K
- Robert HollabaughSouthaven$17K
- Kristopher WhiteheadTupelo$17K
- Harold BlalockJackson$15K
- Jon PoseyTupelo$13K
- Paul FarabaughTupelo$13K
- Clarance FarmerTupelo$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.